NCT03926819View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

April 26, 2023

Study Completion Date

April 26, 2023

Conditions
Anemia, Sickle Cell
Interventions
DRUG

HBI-002

Oral liquid carbon monoxide drug product.

Trial Locations (1)

92121

Contact Company, San Diego

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Hillhurst Biopharmaceuticals, Inc.

INDUSTRY

NCT03926819 - A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers | Biotech Hunter | Biotech Hunter